New drug has been registered — Lacosamide
Mir-Pharm announces successful registration of a new antiepileptic drug
Moscow, December 2024
Lacosamide is an antiepileptic drug. It has been shown in electrophysiological studies that lacosamide selectively increases slow activation of voltagecontrolled pulse-operated sodium channels, which leads to a decrease in increased excitability of neuronal membranes. Moreover, lacosamide has the potential to interact with collapsin response mediator protein-2 (CRMP-2), a phosphoprotein that is expressed mainly in the nervous system and is involved in the processes of neuronal differentiation and control of axonal growth.
Note:
The press release contains information about prescription medications. Use of this information for preparation of publications must be made in accordance with the legislation of the Russian Federation on advertising (including but not limited to Art. 24 of the Federal Law of 13.03.2006 No. 38-FL "On Advertising"), according to which, in particular, advertising of prescription drugs is allowed only in places of medical or pharmaceutical exhibitions, workshops, conferences and other similar events as well as in specialized print media intended for medical and pharmaceutical workers. Failure to comply with the above requirements (namely, mentioning the name of the drug, placing an image of the package or its elements in the media other than specialized print publications intended for medical and pharmaceutical workers) shall entail administrative liability.